Rising Covid-19 cases in China have sent Shenzhen and other cities back into lockdown and there have also been newly confirmed cases in other countries/regions such as the UK, Australia and the EU.
This is bad news for everyone, except of course for the makers of Covid-19 vaccines. The UK, Australia and the EU also happen to be places where Novavax (NVAX) has already signed APAs (advanced purchase agreements). Jefferies analyst Roger Song thinks this could naturally work to the vaccine maker’s advantage.
“While it’s a bit early to call for another wave given current dominant variant remaining Omicron,” the analyst said, “we note this trend could motivate people to get boosted or vaccinated, potentially accelerating the administration of NVAX’s CV19 vaccine and sustaining the demand for dose delivery.”
The EU has committed to purchasing 20-100 million doses, the United Kingdom…
